First drug approved for treatment of spinal muscular atrophy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Spinraza (nusinersen), the first drug to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

SMA is a genetic disease that causes weakness and muscle wasting because of the loss of lower motor neurons controlling movement. SMA is classified in many types based on age of onset, severity of muscle weakness and symptoms. Spinraza is an injection administered into the fluid surrounding the spinal cord, approved for use across the range of spinal muscular atrophy patients.

The efficacy of Spinraza was demonstrated in a clinical trial including 121 patients (aged < 7 mo at the time of 1st dose) with infantile-onset SMA diagnosed before 6 months of age. Patients were randomized to receive an injection of Spinraza, into the fluid surrounding the spinal cord, or undergo a mock procedure without drug injection (a skin prick). In an interim analysis 40% of patients treated with Spinraza achieved improvement in motor milestones (head control, sitting, ability to kick in supine position, rolling, crawling, standing and walking), whereas none of the control patients did.

The findings of additional open-label uncontrolled clinical studies conducted in symptomatic patients (aged 30 days to 15 yrs at the time of 1st dose) and presymptomatic patients (aged 8 days to 42 days at the time of 1st dose) support the clinical efficacy demonstrated in the controlled clinical trial in infantile-onset patients.

The most common side effects reported in patients...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of ED-530XT duodenoscopes by Fujifilm- Updated device design and labeling

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

Read more
  • FDA Drug Updates
  • no comment

FDA approved Endari (L-glutamine) for sickle cell disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Sten Z and M1 Alpha capsules by Andropharm: Contains anabolic steroids

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Ultra-Sten and D-Zine capsules by Hardcore Formulations: Contains anabolic steroids

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Potassium Phosphate and Succinylcholine Chloride by PharMEDium Services: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Succinylcholine Chloride 20mg/mL 5mL syringe by Fagron Sterile Services - Lack of sterility assurance

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Radicava (edaravone) for amyotrophic lateral sclerosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Use of Medtronic’s NavLock Tracker with non-Medtronic instruments can cause spinal injury or death

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rydapt (midostaurin) for acute myeloid leukemia

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Potassium Phosphate and Succinylcholine Chloride by Advanced Pharma - Presence of microbial growth

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Venture catheters by Vascular Solutions- Catheter tip may split or separate during use

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • FDA Drug Updates
  • no comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more